Moolec Science S.A. Q3 FY2023 earnings call

1. Scientific and operational milestones: - Cheese and nutraceutical program: Safflower molecular seeds multiplication campaigns on SPC2 and GLASO, GLASO achieved ~60% expression level for GLA oil yield, 10% above expectations, and received USDA-APHIS regulatory clearance for GLA production safflower plants. - Meat replacement program: New proteins expressed, some reached transformation stage, prototyping scaled up from 3L to 300L, PCR confirmed transgenic events have desired animal genes. 2. Integrations: - Acquired plant-based ingredient capability including a soybean processing facility with 10,000 tons/year capacity, bringing experienced team. - Signed MoU with Bioceres Crop Solutions for Bioceres delivering up to 20,000 tons of HB4 soybeans over 3 years, with payment options. 3. Business plan overview: - Total addressable market for products by 2025 ~$827B, serviceable addressable market ~$37B, driven by double-digit growth in alternative protein industry. - Platform integrated network of farmers, sustainable soybean procurement, industrial demo center, and customer network in 14 countries. - Business plan execution in 4 stages: Stage 1 traditional soybean seeds to TVP, Stage 2 incorporate HB4 soy for sustainability, Stage 3 leverage tech to enhance TVP, Stage 4 have animal proteins in molecular seeds. 4. Financial highlights: - Post business combination, received $10M proceeds with $6M cash/cash equivalents as of March 31, managing cash position, negotiated payment schedules for listing expenses, issued $2M debt, expect to increase operational cash flow while deferring share issuance.

No specific product segment financial performance details provided in a way to extract absolute terms and revenue contribution% as per the transcript requirements. The transcript focuses more on scientific and operational milestones rather than direct financial performance breakdown by segments.

1. Expect to continue low cash burn in R&D with moderate increase in administrative expenses in 2023. 2. Agreement with Bioceres will significantly decrease raw material cash expenses and generate liquidity for R&D and operations. 3. Working on definitive documentation for Bioceres deal to secure raw materials and manage working capital.

Q: Can you talk about Molecular Farming technologies first quarter results?

A: Amit Dhingra discussed safflower with 60% GLA oil expression, soybean at T2 generation with PCR confirmation and expression level confirmation, peas with confirmed gene and greenhouse stages.

Q: How does HB4 soybean differ from traditional soybean?

A: Bioceres' HB4 is drought-tolerant, lowers water and carbon footprint, uses less chemicals, provides traceability from seed to fork.

Q: What is the practical effect the GLA expression levels at 60%, above expectations?

A: Amit Dhingra explained that it's a great milestone where GLA oil expression was expected at 50% and is at 60%, producing value-added product in crop without detrimental effect, positive for economics.